Project 2: Coordinate regulation of liver energy balance by PPARalpha/SRC-1 and FXR/SRC-2
项目2:PPARα/SRC-1和FXR/SRC-2协调调节肝脏能量平衡
基本信息
- 批准号:10421283
- 负责人:
- 金额:$ 35.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adipose tissueAgonistAlbuminsAutophagocytosisBile AcidsBindingBlood Coagulation FactorBrainCarbohydratesCholestasisComplementComplexDrug usageEnterohepatic CirculationFamilyFastingFatty AcidsFibratesGenesGenetic TranscriptionGluconeogenesisGoalsHepaticHepatocyteHomebound PersonsHomeostasisHumanIn VitroIndividualKnockout MiceLigandsLipidsLiverMass Spectrum AnalysisMediatingMediator of activation proteinMetabolicMetabolic PathwayMetabolic syndromeMetabolismMonkeysMusNuclear ReceptorsNutrientOutputPPAR alphaPathway interactionsPharmaceutical PreparationsProductionProteinsProteomicsRXRRegulationRepressionResponse ElementsRoleSerumSiteSystemTestingTherapeutic EffectTranscription CoactivatorTranscription Repressorabsorptionbaseenergy balancefatty acid oxidationfeedinggenome-wideglucose uptakein vivoinsightlipid biosynthesisliver functionmembermetabolomicsnuclear receptor coactivator 1programsreceptorrecruitresponsetranscriptomics
项目摘要
Project 2 - Project Summary
The primary goal of this project is to elucidate the roles of the nuclear receptors PPARα and FXR, and the
coregulators SRC-1 and SRC-2, in the overall control of energy balance in the liver. PPARα is activated in the
fasted state, promoting fatty acid oxidation and gluconeogenesis. FXR is activated in the fed state and represses
gluconeogenesis. Transcriptional functions of PPARα and FXR are mediated by the SRC family of coactivators,
and the members of this Program Project team have shown that SRC-1 and SRC-2 are also central regulators
of liver energy balance. SRC-2 promotes hepatic fed state functions, including glucose uptake and lipid
absorption, and SRC-2 activity is inhibited in the fasted state. In contrast, SRC-1 is induced by fasting and is
essential for activation of gluconeogenesis in the fasted state. We have recently shown that PPARα and FXR
coordinately regulate another fundamental nutrient response in the liver, autophagy, via mutually antagonistic
effects of induction and repression. Our preliminary results identify the hepatic secretome as another, quite
unexpected potential target for complementary control of liver energy balance. Secretion is a very energy
intensive function of the liver, and we have evidence that FXR activates the hepatic secretome, while PPARα
represses it. Based on these results, our overall hypothesis is that PPARα, in concert with SRC-1, and FXR, in
concert with SRC-2, regulate broad pathways of energy utilization and production in the liver to maintain energy
balance. We propose 3 aims to critically test this hypothesis and explore the mechanistic basis for these effects.
1. Complete the genome wide cistromic, transcriptomic, proteomic and metabolomic profiling of the roles of
PPARα and FXR in the fed and fasted liver. 2. Define the role of SRC-1, SRC-2 and NCoR in the opposing
effects of PPARα and FXR in vivo. 3. Define the structural and functional basis for the conversion of FXR/RXR
heterodimers from ligand dependent transcriptional activators on IR-1 sites to ligand dependent transcriptional
repressors on DR-1 sites, and define the coregulators associated with both.
项目2 ----项目概要
本项目的主要目的是阐明核受体PPARα和FXR的作用,
在肝脏能量平衡的总体控制中,协同调节剂SRC-101和SRC-102被激活。
FXR在进食状态下被激活,并抑制脂肪酸氧化和脂肪生成。
PPARα和FXR的转录功能由SRC家族的共激活因子介导,
本计划项目组的成员已经证明,SRC-101和SRC-102也是中央调节器
SRC-102促进肝脏进食状态功能,包括葡萄糖摄取和脂质代谢。
在禁食状态下,SRC-102的活性被抑制,相反,SRC-102的活性被禁食诱导,
我们最近的研究表明,在禁食状态下,PPARα和FXR是激活新生血管的关键。
通过相互拮抗,协调调节肝脏中另一种基本的营养反应,自噬,
我们的初步结果表明,肝分泌组是另一个,
一个意想不到的潜在目标,补充控制肝脏能量平衡。分泌是一个非常能量
我们有证据表明,FXR激活肝分泌组,而PPARα
基于这些结果,我们的总体假设是,PPARα,与SRC-β 1和FXR,
与SRC-102协同作用,调节肝脏中能量利用和产生的广泛途径,以维持能量
平衡。我们提出3个目的来严格检验这一假设,并探讨这些影响的机制基础。
1.完成全基因组顺式组、转录组、蛋白质组和代谢组分析,
2.明确SRC-β 1、SRC-β 2和NCoR在大鼠肝组织中的作用。
3.明确FXR/RXR转化的结构和功能基础
异二聚体从IR-121位点上的配体依赖性转录激活因子到配体依赖性转录激活因子
阻遏物的DR-β 1网站,并定义与两者相关的辅助调节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID D MOORE其他文献
DAVID D MOORE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID D MOORE', 18)}}的其他基金
Project 2: Coordinate regulation of liver energy balance by PPARalpha/SRC-1 and FXR/SRC-2
项目2:PPARα/SRC-1和FXR/SRC-2协调调节肝脏能量平衡
- 批准号:
10153761 - 财政年份:2018
- 资助金额:
$ 35.66万 - 项目类别:
Metabolic Regulation by the Nuclear Receptor CAR
核受体 CAR 的代谢调节
- 批准号:
7003683 - 财政年份:2003
- 资助金额:
$ 35.66万 - 项目类别:
Metabolic Regulation by the Nuclear Receptor CAR
核受体 CAR 的代谢调节
- 批准号:
6567797 - 财政年份:2003
- 资助金额:
$ 35.66万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 35.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 35.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)